For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 29,145 | 21,314* | 28,988 | 24,087 |
| General and administrative | 7,289 | 7,223* | 5,117 | 4,342 |
| Total operating expenses | 36,434 | 28,536 | 34,105 | 28,429 |
| Loss from operations | -36,434 | -28,536* | -34,105 | -28,429 |
| Other expense, net | - | - | 4 | 2 |
| Interest income | 4,606 | 5,097* | 3,832 | 3,857 |
| Interest expense | - | - | - | 0 |
| Other income (expense), net | 8 | -3* | - | - |
| Total other income, net | 4,614 | 5,094* | 3,828 | 3,855 |
| Net loss | -31,820 | -23,443 | -30,277 | -24,574 |
| Net change in unrealized gains (losses) on marketable securities | - | - | 212 | -21 |
| Comprehensive loss | - | - | -30,065 | -24,595 |
| Basic EPS | -0.48 | -0.463 | -0.55 | -0.46 |
| Diluted EPS | -0.48 | -0.463 | -0.55 | -0.46 |
| Basic Average Shares | 55,172,410 | 50,679,416 | 44,067,059 | 42,095,951 |
| Diluted Average Shares | 55,172,410 | 50,679,416 | 44,067,059 | 42,095,951 |
Oruka Therapeutics, Inc. (ORKA)
Oruka Therapeutics, Inc. (ORKA)